share_log

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

週一盤後交易時段，12只醫療保健股走勢
Benzinga ·  2023/09/19 05:31

Gainers

獲勝者

  • Longeveron Inc. - Subscription Right (NASDAQ:LGVNR) shares moved upwards by 536.4% to $0.01 during Monday's after-market session. At the close, Longeveron Inc. - Subscription Right's trading volume reached 238.3K shares. This is 42.8% of its average volume over the last 100 days.
  • Avinger (NASDAQ:AVGR) shares increased by 49.42% to $9.07. Trading volume for this security closed at 2.7 million, accounting for 34966.7% of its average full-day volume over the last 100 days. The company's market cap stands at $6.5 million.
  • Elutia (NASDAQ:ELUT) shares rose 45.16% to $1.8. Today's trading volume for this security ended up closing at 1.8 million shares, which is 815.2 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $29.2 million.
  • Aclarion (NASDAQ:ACON) shares rose 20.9% to $0.52. Today's trading volume for this security ended up closing at 177.2K shares, which is 359.5 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million.
  • Singular Genomics Sys (NASDAQ:OMIC) stock increased by 10.81% to $0.44. The market value of their outstanding shares is at $31.9 million.
  • Stereotaxis (AMEX:STXS) shares increased by 8.69% to $1.75. The market value of their outstanding shares is at $141.5 million.
  • Longeveron Inc.-訂閱權 納斯達克股票代碼：LGVNR）股價在週一的盤後交易時段上漲536.4％，至0.01美元。收盤時，Longeveron Inc.——訂閱權的交易量達到23.83萬股。這是其過去100天平均交易量的42.8％。
  • Avinger 納斯達克股票代碼：AVGR）股價上漲49.42％，至9.07美元。該證券的交易量收於270萬，佔其過去100天平均全天交易量的34966.7％。該公司的市值爲650萬美元。
  • Elutia 納斯達克股票代碼：ELUT）股價上漲45.16％，至1.8美元。該證券今天的交易量最終收於180萬股，佔其過去100天平均交易量的815.2％。他們流通股的市值爲2920萬美元。
  • Aclarion 納斯達克股票代碼：ACON）股價上漲20.9％，至0.52美元。該證券今天的交易量最終收於17.72萬股，佔其過去100天平均交易量的359.5％。他們流通股的市值爲420萬美元。
  • 奇異基因組學系統 納斯達克股票代碼：OMIC）股價上漲10.81％，至0.44美元。他們流通股的市值爲3190萬美元。
  • 刻板印象 美國證券交易所股票代碼：STXS）股價上漲8.69％，至1.75美元。他們流通股的市值爲1.415億美元。

Losers

失敗者

  • Kinnate Biopharma (NASDAQ:KNTE) shares decreased by 16.5% to $1.42 during Monday's after-market session. The market value of their outstanding shares is at $66.8 million.
  • T2 Biosystems (NASDAQ:TTOO) stock fell 11.42% to $0.41. T2 Biosystems's trading volume hit 63.5 million shares by close, accounting for 59.5% of its average volume over the last 100 days. The company's market cap stands at $135.6 million.
  • Redhill Biopharma (NASDAQ:RDHL) shares declined by 11.21% to $0.72. Redhill Biopharma's trading volume hit 5.8 million shares by close, accounting for 2645.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million.
  • Perspective Therapeutics (AMEX:CATX) stock decreased by 10.85% to $0.29. Perspective Therapeutics's trading volume hit 1.1 million shares by close, accounting for 374.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $80.0 million.
  • Tempest Therapeutics (NASDAQ:TPST) shares decreased by 9.49% to $0.45. The market value of their outstanding shares is at $5.9 million.
  • CohBar (NASDAQ:CWBR) stock declined by 8.79% to $2.7. The company's market cap stands at $7.8 million. See Also:
  • 金納特生物製藥 納斯達克股票代碼：KNTE）股價在週一的盤後交易時段下跌16.5％，至1.42美元。他們流通股的市值爲6,680萬美元。
  • T2 生物系統 納斯達克股票代碼：TTOO）股價下跌11.42％，至0.41美元。截至收盤時，T2 Biosystems的交易量達到6,350萬股，佔其過去100天平均交易量的59.5％。該公司的市值爲1.356億美元。
  • 紅山生物製藥 納斯達克股票代碼：RDHL）股價下跌11.21％，至0.72美元。Redhill Biopharma的交易量收盤達到580萬股，佔其過去100天平均交易量的2645.9％。他們流通股的市值爲420萬美元。
  • 透視療法 美國證券交易所股票代碼：CATX）股票下跌10.85％，至0.29美元。Persective Therapeutics的交易量截至收盤時達到110萬股，佔其過去100天平均交易量的374.9％。他們流通股的市值爲8,000萬美元。
  • 暴風雨療法 納斯達克股票代碼：TPST）股價下跌9.49％，至0.45美元。他們流通股的市值爲590萬美元。
  • COHBar 納斯達克股票代碼：CWBR）股價下跌8.79％，至2.7美元。該公司的市值爲780萬美元。 另請參閱：

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自動內容引擎生成，並由編輯審閱。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論